BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...
Patients with low or intermediate-1 (int-1) International Prognostic Scoring System (IPSS) risk myelodysplastic syndromes (MDS) have a median survival of 5.7 and 3.5 years, respectively, when treated ...
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women Two 16-week randomized, double-blind, placebo-controlled ...
This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
Association of diabetes mellitus with arsenic trioxide (ATO) evaluated in the treatment of acute promyelocytic leukemia (APL). Breast (N= 175) 9.8 (1.1) 11.3 (1.5) 1.5 (1.6) 2.3 Lung (N= 240) 9.1 (0.9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results